Patient Square Capital LP Lowers Holdings in Kymera Therapeutics, Inc. $KYMR

Patient Square Capital LP reduced its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 33.9% during the 3rd quarter, according to its most recent filing with the SEC. The firm owned 92,592 shares of the company’s stock after selling 47,408 shares during the period. Kymera Therapeutics makes up approximately 1.4% of Patient Square Capital LP’s portfolio, making the stock its 12th biggest holding. Patient Square Capital LP owned 0.13% of Kymera Therapeutics worth $5,241,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of the stock. PNC Financial Services Group Inc. grew its holdings in Kymera Therapeutics by 506.6% during the second quarter. PNC Financial Services Group Inc. now owns 922 shares of the company’s stock worth $40,000 after acquiring an additional 770 shares during the period. Bessemer Group Inc. boosted its position in Kymera Therapeutics by 652.0% in the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock worth $53,000 after purchasing an additional 815 shares in the last quarter. Osaic Holdings Inc. grew its stake in shares of Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock worth $48,000 after purchasing an additional 1,083 shares during the period. Raymond James Financial Inc. purchased a new position in shares of Kymera Therapeutics during the 2nd quarter valued at approximately $73,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Kymera Therapeutics in the 2nd quarter valued at $116,000.

Wall Street Analyst Weigh In

KYMR has been the subject of a number of recent analyst reports. Truist Financial lifted their price objective on shares of Kymera Therapeutics from $80.00 to $116.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Stephens raised their target price on Kymera Therapeutics from $65.00 to $110.00 and gave the company an “overweight” rating in a research report on Thursday, December 11th. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Jefferies Financial Group raised their price objective on Kymera Therapeutics from $73.00 to $122.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Finally, Royal Bank Of Canada boosted their price objective on Kymera Therapeutics from $70.00 to $103.00 and gave the company an “outperform” rating in a research report on Tuesday, December 16th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $117.00.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock opened at $87.40 on Monday. The stock has a market capitalization of $6.29 billion, a P/E ratio of -24.35 and a beta of 2.21. The business has a 50 day simple moving average of $77.70 and a two-hundred day simple moving average of $63.81. Kymera Therapeutics, Inc. has a 12 month low of $19.44 and a 12 month high of $103.00.

Insider Buying and Selling

In other news, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $89.76, for a total transaction of $448,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Jared Gollob sold 49,307 shares of the firm’s stock in a transaction dated Monday, December 8th. The stock was sold at an average price of $88.67, for a total transaction of $4,372,051.69. Following the completion of the transaction, the insider directly owned 109,992 shares in the company, valued at approximately $9,752,990.64. This represents a 30.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 420,895 shares of company stock worth $37,778,351 in the last ninety days. Company insiders own 16.01% of the company’s stock.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.